National Health and Health Commission deployed national monitoring of clinical application of antineoplastic drugs

On January 21, 2019, the National Health Commission held a national teleconference to deploy the monitoring of clinical application of anti-tumor drugs Wang Hesheng, deputy director of the National Health Commission, attended the meeting and made a speech Wang Hesheng summarized the positive results of cancer prevention and treatment in China, analyzed the current challenges, and put forward clear requirements for further cancer drug management Wang Hesheng pointed out that the CPC Central Committee and the State Council attach great importance to cancer prevention and control, especially since 2018, a series of major measures have been taken to reduce the drug cost burden of cancer patients The national health and Health Commission has actively promoted 17 kinds of national health insurance negotiation anticancer drugs to enter the hospital On the one hand, cancer patients can use them, and on the other hand, they can use them reasonably according to the standard guidelines As of January 10, 2019, 620000 boxes of negotiated anticancer drugs have been used nationwide Wang Hesheng stressed that the National Health Commission organized the National Cancer Center to develop the national monitoring network for the clinical application of antineoplastic drugs The local health departments and medical institutions should strengthen the organization and leadership, carefully report, analyze and feed back the monitoring data, and promote the rational clinical use of drugs The meeting also provided training on the reporting of monitoring data Health departments at provincial, prefecture and municipal levels and relevant medical institutions participated in the sub conference.